FIGURE 4 from Nuclear Export Inhibitor Selinexor Enhances Oncolytic Myxoma Virus Therapy against Cancer

Authors:
Open Access
Publisher website
Google Scholar
Abstract
Combination of selinexor and oncolytic MYXV significantly reduced human cancer cells proliferation. A, Schematic representation of the cell proliferation assay protocol using Click-iT EdU kit. B, PANC-1 cells were left untreated (mock) or treated with selinexor, vMyx-GFP or a combination of selinexor + vMyx-GFP and cell proliferation assay was performed using Click-iT EdU kit. The images were taken using a fluorescence microscope. The assays were performed in triplicate and a representative is shown. C, Quantification of the number of cells showing labeling with EdU 594 (red fluorescence). A minimum of 100 cells were used for analysis from fluorescence images taken in B. Data represent mean ± SD and n = 3. Statistically significant differences among the different treatments are indicated. **, P < 0.01; ***, P < 0.001. PANC-1 (D and E) and Colo205 (F and G) cells in 96-well plates were left untreated (mock) or treated with selinexor, vMyx-GFP, a combination of selinexor + vMyx-GFP or vMyx-M11L-KO as control and cell proliferation assay was performed using CyQUANT NF cell proliferation assay kit. Data represent mean ± SD and n = 4. Statistically significant differences among the different treatments are indicated. ns, P > 0.05; *, P < 0.05; **, P < 0.01; ***, P < 0.001.